- Australian medical imaging software provider ImExHS got Thai FDA approval for its PACS technology.
- The company received the first Aquila in the Cloud order from BJC.
- IME has also signed an international software distribution agreement with BJC Healthcare company.
The leading Australian medical imaging software provider ImExHS Limited’s shares (ASX:IME) closed in green as the company announced to received Thai FDA approval.
As per the release, IME has spread its wings in the Thai market after getting Food and Drug Administration (FDA) approval from Thailand for its PACS technology. Also known as HIRUKO Essential software suite, PACS is an IME's unique Imaging software suite.
Related read - EnviroSuite’s (ASX:EVS) total ARR nears AU$50 million
The company also revealed that it had signed an international software distribution agreement with BJC Healthcare Company, a part of the Berli Jucker Group, a leading medical equipment provider.
IME has received the first Aquila in the Cloud order from BJC for its Bangkok-based Siriraj Hospital's Mobile Stroke Unit. The company is excited to launch its user-friendly medical imaging platform to the Thailand market as the country’s rapidly ageing population is driving significant demand for healthcare services.
On the development, co-founder, and CEO of ImExHs Dr German Arango said:
As Siriraj is one of the oldest and largest Thai hospitals, with over 2,000 beds, this contract is likely to add significant value to IME's business ventures.